{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["George RE"],"funding":["NCRR NIH HHS","NCI NIH HHS","NINDS NIH HHS"],"pagination":["629-38"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3025700"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["55(4)"],"pubmed_abstract":["<h4>Background</h4>Demethylating agents may alter the expression of genes involved in chemotherapy resistance. We conducted a phase I trial to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors.<h4>Procedure</h4>Stratum A included children with any solid tumor; Stratum B included neuroblastoma patients only. Patients received a 1-hr decitabine infusion for 7 days, followed by doxorubicin (45 mg/m(2)) and cyclophosphamide (1 g/m(2)) on day 7. Pharmacokinetic studies were performed after the first dose of decitabine. Biological studies included methylation and gene expression analyses of caspase-8, MAGE-1 and fetal hemoglobin (HbF), and expression profiling of pre- and post"],"journal":["Pediatric blood & cancer"],"pubmed_title":["Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study."],"pmcid":["PMC3025700"],"funding_grant_id":["K08NS047983","U01 CA97452","K08 NS047983","U01 CA097452","M01 RR00188","R01 CA067938","M01 RR000188"],"pubmed_authors":["Krailo M","George RE","Finkelstein D","Neuberg D","Blaney SM","Diller L","Adamson PC","Zhu K","Ingle AM","Lahti JM","Reid JM"],"additional_accession":[]},"is_claimable":false,"name":"Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.","description":"<h4>Background</h4>Demethylating agents may alter the expression of genes involved in chemotherapy resistance. We conducted a phase I trial to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors.<h4>Procedure</h4>Stratum A included children with any solid tumor; Stratum B included neuroblastoma patients only. Patients received a 1-hr decitabine infusion for 7 days, followed by doxorubicin (45 mg/m(2)) and cyclophosphamide (1 g/m(2)) on day 7. Pharmacokinetic studies were performed after the first dose of decitabine. Biological studies included methylation and gene expression analyses of caspase-8, MAGE-1 and fetal hemoglobin (HbF), and expression profiling of pre- and post","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Oct","modification":"2025-04-04T00:28:57.315Z","creation":"2019-03-27T00:38:22Z"},"accession":"S-EPMC3025700","cross_references":{"pubmed":["20589651"],"doi":["10.1002/pbc.22607"]}}